Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient

Document Type

Journal Article

Publication Date

1-1-1995

Journal

American Journal of Kidney Diseases

Volume

25

Issue

4

DOI

10.1016/0272-6386(95)90138-8

Keywords

Arteriovenous graft; clotting; end-stage renal disease; hemodialysis; heparin; heparin-dependent platelet antibody

Abstract

Clotting of vascular access in hemodialysis patients remains a significant problem. The routine use of heparin to anticoagulate the blood during hemodialysis has been helpful in increasing the life span of vascular access in these patients. However, the use of heparin is not without complications. Heparin-induced thrombocytopenia is one of the well-recognized drug-induced thrombocytopenic disorders that by itself usually does not cause serious morbidity. A small proportion of these patients concomitantly develop "paradoxic" acute thrombotic complications. Myocardial infarction, ischemic damage to lower extremities leading to amputation, and cerebrovascular accident with permanent neurologic deficits or leading to death are just some of the disastrous complications. We report a case of paradoxic clotting of the hemoaccess in a patient receiving hemodialysis treatment associated with the use of heparin that has not been previously described. The patient had heparin-dependent platelet antibody resulting in a decrease in platelet count and clotting of the hemoaccess. © 1995.

Link to Full Text

Share

COinS